97 results on '"Komatsu, Kanji"'
Search Results
2. Approach to Evaluating QT Prolongation of Quetiapine Fumarate in Late Stage of Clinical Development Using Concentration-QTc Modeling and Simulation in Japanese Patients With Bipolar Disorder
3. Population Pharmacokinetics Analysis of Quetiapine Extended-release Formulation in Japanese Patients with Bipolar Depression
4. A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1–4, as a single dose and multiple doses in patients with solid malignancies
5. Population Pharmacokinetic Modeling and Simulation of Pudexacianinium (ASP5354) for Dose Setting of a Phase 2 First‐in‐Patient Study: A Novel Imaging Agent for Intraoperative Ureter Visualization during Abdominopelvic Surgery.
6. Population Pharmacokinetic Modeling and Simulation of Pudexacianinium (ASP5354) for Dose Setting of a Phase 2 First‐in‐Patient Study: A Novel Imaging Agent for Intraoperative Ureter Visualization during Abdominopelvic Surgery
7. Population pharmacokinetics of roxadustat in Japanese dialysis‐dependent chronic kidney disease patients with anaemia
8. O1-9-2 - Phase I / II study of ASP8273 in patients with non-small-cell lung cancer (NSCLC) harboring EGFR activating mutations
9. Physiologically‐Based Pharmacokinetic Modeling for the Prediction of a Drug–Drug Interaction of Combined Effects on P‐glycoprotein and Cytochrome P450 3A
10. A phase 2a, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral gonadotropin-releasing hormone antagonist, ASP1707, in postmenopausal female patients with rheumatoid arthritis taking methotrexate
11. Population pharmacokinetics of roxadustat in Japanese dialysis‐dependent chronic kidney disease patients with anaemia.
12. Abstracts of selected papers presented at the 78th general meeting of the Japanese Society of Gastroenterology
13. A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1–4, as a single dose and multiple doses in patients with solid malignancies
14. Bayesian dose-finding phase I trial design incorporating pharmacokinetic assessment in the field of oncology
15. ASP 8273 tolerability and antitumor activity in tyrosine kinase inhibitor‐naïve Japanese patients withEGFRmutation‐positive non‐small‐cell lung cancer
16. Tolerability and antitumor activity of ASP8273 in TKI-naive Japanese subjects with EGFR mutation–positive non-small cell lung cancer.
17. P3.02b-086 ASP8273 Tolerability and Antitumor Activity in TKI-Naïve Japanese Subjects with EGFRmut+ NSCLC: Preliminary Results
18. Clinical significance of glucagon provocation test in the diagnosis of hypergastrinemia
19. Proceedings of the 68th Annual Meeting from March 28th–30th, 1982—Hiroshima, Japan
20. Proceedings of the 25th Annual Meeting from October 13–15, 1983—Yamaguchi, Japan
21. ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor‐naïve Japanese patients with EGFR mutation‐positive non‐small‐cell lung cancer.
22. Phase I / II study of ASP8273 in patients with non-small-cell lung cancer (NSCLC) harboring EGFR activating mutations
23. ASP8273, a mutant-selective irreversible EGFR inhibitor in patients (pts) with NSCLC harboring EGFR activating mutations: Preliminary results of first-in-human phase I study in Japan.
24. Practical Aspects of Population Pharmacokinetics & Pharmacodynamics
25. DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1α in type 2 diabetic patients with incipient nephropathy
26. Correction to Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MAPKAP-K2) as an Antiinflammatory Target: Discovery and in Vivo Activity of Selective Pyrazolo[1,5-a]pyrimidine Inhibitors Using a Focused Library and Structure-Based Optimization Approach
27. Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MAPKAP-K2) as an Antiinflammatory Target: Discovery and in Vivo Activity of Selective Pyrazolo[1,5-a]pyrimidine Inhibitors Using a Focused Library and Structure-Based Optimization Approach
28. Statistical Models for Model-Based Drug Development
29. Small Intestinal Follicular Lymphoma with Multiple Tumor Formations Diagnosed by Double-Balloon Enteroscopy
30. Pseudogout Showing Meningoencephalitic Symptoms: Crowned Dens Syndrome
31. A Multicentre Randomized Controlled Trial of Recombinant Interferon-Alpha-2a in the Treatment of Patients with Chronic Hepatitis C
32. A CASE OF MUCINOUS CYSTADENOCARCINOMA OF THE PANCREAS TREATED BY TOTAL PANCREATECTOMY AFTER A FOUR-YEAR FOLLOW-UP
33. Indications of the Laparoscopic Cholecystectomy
34. Mitogen-Activated ProteinKinase-Activated ProteinKinase 2 (MAPKAP-K2) as an Antiinflammatory Target: Discovery andin Vivo Activity of Selective Pyrazolo[1,5-a]pyrimidineInhibitors Using a Focused Library and Structure-Based OptimizationApproach.
35. A Model‐Based Trial Design With a Randomization Scheme Considering Pharmacokinetics Exposure for Dose Optimization in Oncology.
36. Inhibition of Biliary Excretion of Methotrexate by Probenecid in Rats: Quantitative Prediction of Interaction from in Vitro Data
37. Prediction of in Vivo Drug-Drug Interactions between Tolbutamide and Various Sulfonamides in Humans Based on in Vitro Experiments
38. Mechanism-Based model for beta cell function in healthy individuals and patients with type 2 diabetes for intravenous and oral glucose
39. Effect of Clinofibrate (LipoclinR) on Serum Cholesterol Level in Hypercholesterolemic Diabetics
40. Field Study on Obese Women in Rural District
41. Study on Labor and Health Problems of the Middle and High Aged in Rural Districts; from the view point of laboratory blood findings
42. Characteristics of decrease of plasma gastrin by glucagon in man.
43. Epidemiological and clinical studies of liver cirrhosis in a rural area.
44. A 10 year follow-up of diabetes in a rural area of Japan using the 50g oral glucose tolerance test.
45. Prevalence of diabetes mellitus in a rural area of Japan: By 75g OGTT.
46. Disturbances of the alimentary tract motility and hypermotilinemia in the patients with diabetes mellitus.
47. Serum group I pepsinogen (PG I) levels and their changes in the healing process of the ulcer in patients with and without unoperated recurrent ulcer.
48. Mass Survey for Diabetes Mellitus by a Glucose Tolerance Test (GTT) as the First Screening
49. Natural History of Diabetes Mellitus with Special Reference to Age of Onset and Vascular Complications
50. Occurrence of Child Peptic Ulcer in A Rural Community
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.